Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.66 |
| ▸ | MGLL | Q99685 | 10/20 | 0.52 |
| ▸ | FAAH | O00519 | 9/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | APAF1 | O14727 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TDP2 | O95551 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426681 | 0.82 | MGLL (0.71) | MGLLFAAHHTT | |
| SCHEMBL2732640 | 0.81 | DGAT1 (1.00) | DGAT1CYP2D6HTTHPGDALDH1A1 | |
| SCHEMBL427685 | 0.77 | MGLL (0.60) | MGLLFAAH | |
| SCHEMBL14936325 | 0.77 | DGAT1 (0.66) | DGAT1MGLLFAAHHPGDKMT2A | |
| SCHEMBL2405870 | 0.76 | DGAT1 (0.60) | DGAT1MGLLFAAHHPGDALDH1A1 | |
| SCHEMBL13275318 | 0.75 | DGAT1 (0.55) | DGAT1MGLLFAAHHPGDKMT2A | |
| SCHEMBL242196 | 0.73 | CYP2D6 (0.60) | DGAT1CYP2D6HTTHPGDALDH1A1 | |
| SCHEMBL13453106 | 0.73 | DGAT1 (0.77) | DGAT1CYP2D6HTTHPGDALDH1A1 | |
| SCHEMBL426727 | 0.71 | MGLL (0.60) | MGLLFAAH | |
| SCHEMBL1520814 | 0.71 | DGAT1 (0.72) | DGAT1CYP2D6HTTHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | disclosed |
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | disclosed |
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | disclosed |
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2013-11-14 | — | — | US | disclosed |
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2013-11-14 | — | — | US | disclosed |
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2013-11-14 | — | — | US | disclosed |
| WO-2012101654-A2 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PVT. LTD (IN) | 2012-08-02 | — | — | WO | disclosed |
| EP-1300401-B1 | THIAZOLE DERIVATIVES FOR USE AS ANTIINFLAMMATORIES | DAINIPPON SUMITOMO PHARMA CO (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-7396842-B2 | Five-membered cyclic compounds | DIANIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| EP-1669070-A2 | 2-imino-thiazolidine and -oxazolidine derivatives for use as antiinflammatory agents | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-06-14 | — | — | EP | disclosed |
| US-20050222226-A1 | Five-membered cyclic compounds | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED | 2005-10-06 | — | — | US | disclosed |
| US-6919361-B2 | Five-membered-ring compound | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-07-19 | — | — | US | disclosed |
| US-20040072827-A1 | Five-membered-ring compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1300401-A1 | FIVE-MEMBERED-RING COMPOUND | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072827-A1 | Five-membered-ring compound | EPX, IL5, CCR9 | DGAT1 2980/4885MGLL 4140/4885FAAH 2965/4885 |
| US-20050222226-A1 | Five-membered cyclic compounds | EPX, CCL11, CCR9 | DGAT1 3197/4885MGLL 3204/4885FAAH 2475/4885 |
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | MTOR, MAPKAP1, PIK3R5 | DGAT1 2175/4885MGLL 4430/4885FAAH 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.